KCa3.1 Inhibition of Macrophages Suppresses Inflammatory Response Leading to Endothelial Damage in a Cell Model of Kawasaki Disease

References

• McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation. 2017;135(17):17. doi:10.1161/CIR.0000000000000484
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324(23):1633–1639. doi:10.1056/NEJM199106063242305
   PubMed Web of Science ®Google Scholar
• Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94(6):1379–1385. doi:10.1161/01.CIR.94.6.1379
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007–2008 nationwide survey. J Epidemiol. 2010;20(4):302–307. doi:10.2188/jea.JE20090180
   PubMed Web of Science ®Google Scholar
• Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr. 1993;123(4):657–659.
   PubMed Web of Science ®Google Scholar
• Al-Mayouf SM. The use of corticosteroid therapy in refractory Kawasaki patients. Clin Rheumatol. 2004;23(1):11–13.
   PubMed Web of Science ®Google Scholar
• Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93(2):142–146.
   PubMed Web of Science ®Google Scholar
• Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–838.
   PubMed Web of Science ®Google Scholar
• Nagatomo Y, Muneuchi J, Nakashima Y, et al. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease. Int J Cardiol. 2018;271:317–321.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. 2011;30(10):871–876. doi:10.1097/INF.0b013e318220c3cf
   PubMed Web of Science ®Google Scholar
• Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, Phase 3 trial. Lancet. 2019;393(10176):1128–1137.
   PubMed Web of Science ®Google Scholar
• Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr. 2004;163(4–5):263–264. doi:10.1007/s00431-003-1267-y
   PubMed Web of Science ®Google Scholar
• Koga M, Ishihara T, Takahashi M, Umezawa Y, Furukawa S. Activation of peripheral blood monocytes and macrophages in Kawasaki disease: ultrastructural and immunocytochemical investigation. Pathol Int. 1998;48(7):512–517. doi:10.1111/j.1440-1827.1998.tb03942.x
   PubMed Web of Science ®Google Scholar
• Ichiyama T, Yoshitomi T, Nishikawa M, et al. NF-kappaB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol. 2001;99(3):373–377. doi:10.1006/clim.2001.5026
   PubMed Web of Science ®Google Scholar
• Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol. 2005;141(3):381–387. doi:10.1111/j.1365-2249.2005.02821.x
   PubMed Web of Science ®Google Scholar
• Hara T, Nakashima Y, Sakai Y, Nishio H, Motomura Y, Yamasaki S. Kawasaki disease: a matter of innate immunity. Clin Exp Immunol. 2016;186(2):134–143. doi:10.1111/cei.12832
   PubMed Web of Science ®Google Scholar
• Ohashi R, Fukazawa R, Shimizu A, et al. M1 macrophage is the predominant phenotype in coronary artery lesions following Kawasaki disease. Vasc Med. 2019;24(6):484–492. doi:10.1177/1358863X19878495
   PubMed Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27(1):451–483. doi:10.1146/annurev.immunol.021908.132532
   PubMed Web of Science ®Google Scholar
• Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229(2):176–185. doi:10.1002/path.4133
   PubMed Web of Science ®Google Scholar
• Furukawa S, Matsubara T, Jujoh K, et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol. 1988;48(2):247–251. doi:10.1016/0090-1229(88)90088-8
   PubMedGoogle Scholar
• Lehman TJ, Walker SM, Mahnovski V, McCurdy D. Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum. 1985;28(6):652–659. doi:10.1002/art.1780280609
   PubMedGoogle Scholar
• Rosenkranz ME, Schulte DJ, Agle LMA, et al. TLR2 and MyD88 Contribute to Lactobacillus casei extract–induced focal coronary arteritis in a mouse model of kawasaki disease. Circulation. 2005;112(19):2966–2973. doi:10.1161/CIRCULATIONAHA.105.537530
   PubMed Web of Science ®Google Scholar
• Lee Y, Schulte DJ, Shimada K, et al. Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation. 2012;125(12):1542–1550. doi:10.1161/CIRCULATIONAHA.111.072769
   PubMed Web of Science ®Google Scholar
• Lin IC, Suen JL, Huang SK, et al. Dectin-1/Syk signaling is involved in Lactobacillus casei cell wall extract-induced mouse model of Kawasaki disease. Immunobiology. 2013;218(2):201–212. doi:10.1016/j.imbio.2012.04.004
   PubMed Web of Science ®Google Scholar
• Sforna L, Megaro A, Pessia M, Franciolini F, Catacuzzeno L. Structure, Gating and Basic Functions of the Ca2+-activated K Channel of Intermediate Conductance. Curr Neuropharmacol. 2018;16(5):608–617. doi:10.2174/1570159X15666170830122402
   PubMed Web of Science ®Google Scholar
• Xu R, Li C, Wu Y, et al. Role of KCa3.1 channels in macrophage polarization and its relevance in atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2017;37(2):226–236. doi:10.1161/ATVBAHA.116.308461
   PubMed Web of Science ®Google Scholar
• Ma X-Z, Pang Z-D, Wang J-H, et al. The role and mechanism of KCa3.1 channels in human monocyte migration induced by palmitic acid. Exp Cell Res. 2018;369(2):208–217. doi:10.1016/j.yexcr.2018.05.020
   PubMed Web of Science ®Google Scholar
• Kaushal V, Koeberle PD, Wang Y, Schlichter LC. The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci. 2007;27(1):234–244. doi:10.1523/JNEUROSCI.3593-06.2007
   PubMed Web of Science ®Google Scholar
• Kang H, Kerloc’h A, Rotival M, et al. Kcnn4 is a regulator of macrophage multinucleation in bone homeostasis and inflammatory disease. Cell Rep. 2014;8(4):1210–1224. doi:10.1016/j.celrep.2014.07.032
   PubMed Web of Science ®Google Scholar
• Hua X, Deuse T, Chen Y-J, et al. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease. Transplantation. 2013;95(2):285–292. doi:10.1097/TP.0b013e318275a2f4
   PubMed Web of Science ®Google Scholar
• Chen Y-J, Raman G, Bodendiek S, O’Donnell ME, Wulff H. The KCa3.1 Blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cerebral Blood Flow Metabo. 2011;31(12):2363–2374. doi:10.1038/jcbfm.2011.101
   PubMed Web of Science ®Google Scholar
• Toyama K, Wulff H, Chandy KG, et al. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest. 2008;118(9):3025–3037. doi:10.1172/JCI30836
   PubMed Web of Science ®Google Scholar
• Okitsu-Negishi S, Nakano I, Suzuki K, Hashira S, Abe T, Yoshino K. The induction of cardioangitis by Lactobacillus casei cell wall in mice. I. The cytokine production from murine macrophages by Lactobacillus casei cell wall extract. Clin Immunol Immunopathol. 1996;78(1):30–40. doi:10.1006/clin.1996.0005
   PubMedGoogle Scholar
• Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol. 2020;16(7):391–405.
   PubMed Web of Science ®Google Scholar
• Gao L, Fu S, Wang W, Xie C, Zhang Y, Gong F. Notch4 signaling pathway in a Kawasaki disease mouse model induced by Lactobacillus casei cell wall extract. Exp Ther Med. 2017;13(6):3438–3442. doi:10.3892/etm.2017.4434
   PubMed Web of Science ®Google Scholar
• Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol. 2010;3(3):385–396. doi:10.1586/ecp.10.11
   PubMedGoogle Scholar
• Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis. 2001;184(7):940–943. doi:10.1086/323155
   PubMed Web of Science ®Google Scholar
• Schulte DJ, Yilmaz A, Shimada K, et al. Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease. J Immunol. 2009;183(8):5311–5318. doi:10.4049/jimmunol.0901395
   PubMed Web of Science ®Google Scholar
• Ueno Y, Takano N, Kanegane H, et al. The acute phase nature of interleukin 6: studies in Kawasaki disease and other febrile illnesses. Clin Exp Immunol. 1989;76(3):337–342.
   PubMed Web of Science ®Google Scholar
• Maury CP, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med. 1988;319(25):1670–1671.
   PubMed Web of Science ®Google Scholar
• Wong M, Silverman ED, Fish EN. Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease. J Rheumatol. 1997;24(6):1179–1185.
   PubMed Web of Science ®Google Scholar
• Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol. 2006;176(10):6294–6301. doi:10.4049/jimmunol.176.10.6294
   PubMed Web of Science ®Google Scholar
• Wakita D, Kurashima Y, Crother TR, et al. Role of interleukin-1 signaling in a mouse model of kawasaki disease-associated abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2016;36(5):886–897. doi:10.1161/ATVBAHA.115.307072
   PubMed Web of Science ®Google Scholar
• Senzaki H. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Arch Dis Child. 2006;91(10):847–851. doi:10.1136/adc.2005.087437
   PubMed Web of Science ®Google Scholar
• Lau AC, Duong TT, Ito S, Wilson GJ, Yeung RSM. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol. 2009;157(2):300–309. doi:10.1111/j.1365-2249.2009.03949.x
   PubMed Web of Science ®Google Scholar
• Yu X, Hirono K-I, Ichida F, et al. Enhanced iNOS expression in leukocytes and circulating endothelial cells is associated with the progression of coronary artery lesions in acute Kawasaki disease. Pediatr Res. 2004;55(4):688–694.
   PubMed Web of Science ®Google Scholar
• Adewuya O, Irie Y, Bian K, Onigu-Otite E, Murad F. Mechanism of vasculitis and aneurysms in Kawasaki disease: role of nitric oxide. Nitric Oxide. 2003;8(1):15–25.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Hashimoto N, Naritomi H, et al. Prevention of rat cerebral aneurysm formation by inhibition of nitric oxide synthase. Circulation. 2000;101(21):2532–2538.
   PubMed Web of Science ®Google Scholar
• Freise C, Querfeld U. Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34. Pharmacological Research. 2014;85:6–14.
   PubMed Web of Science ®Google Scholar
• Yin W, Wang X, Ding Y, et al. Expression of nuclear factor -κBp65 in mononuclear cells in Kawasaki disease and its relation to coronary artery lesions. Indian J Pediatr. 2011;78(11):1378–1382.
   PubMed Web of Science ®Google Scholar
• Tian J, An X, Niu L. Correlation between NF-kappaB signal pathway-mediated caspase-4 activation and Kawasaki disease. Exp Ther Med. 2017;13(6):3333–3336.
   PubMed Web of Science ®Google Scholar
• Zhou X, Yang W, Ca LJ. 2+- and protein kinase C-dependent signaling pathway for nuclear factor-kappaB activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-alpha production in lipopolysaccharide-stimulated rat peritoneal macrophages. J Biol Chem. 2006;281(42):31337–31347.
   PubMed Web of Science ®Google Scholar
• Wei T, Wang Y, Xu W, Liu Y, Chen H, Yu Z. KCa3.1 deficiency attenuates neuroinflammation by regulating an astrocyte phenotype switch involving the PI3K/AKT/GSK3β pathway. Neurobiol Dis. 2019;132:10487.
   Web of Science ®Google Scholar
• Kim SH, Park SY, Park YL, Myung DS, Rew JS, Joo YE. Chlorogenic acid suppresses lipopolysaccharide-induced nitric oxide and interleukin1beta expression by inhibiting JAK2/STAT3 activation in RAW264.7 cells. Mol Med Rep. 2017;16(6):9224–9232.
   PubMed Web of Science ®Google Scholar
• Qi Z, Qi S, Ling L, Lv J, Feng Z. Salidroside attenuates inflammatory response via suppressing JAK2-STAT3 pathway activation and preventing STAT3 transfer into nucleus. Int Immunopharmacol. 2016;35:265–271.
   PubMed Web of Science ®Google Scholar
• Li R, Hong P, Zheng X. beta-carotene attenuates lipopolysaccharide-induced inflammation via inhibition of the NF-kappaB, JAK2/STAT3 and JNK/p38 MAPK signaling pathways in macrophages. Anim Sci J. 2019;90(1):140–148.
   PubMed Web of Science ®Google Scholar
• Park JS, Lee J, Lim MA, et al. JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T Cells and Th17 cells. J Immunol. 2014;192(9):4417–4424.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li J, Qin JJ, et al. Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages. J Lipid Res. 2017;58(5):895–906.
   PubMed Web of Science ®Google Scholar
• Qi XL, Chen LL, Sun XG, Li XM, Zhao LH, Kong DJ. 1,25-Dihydroxyvitamin D3 regulates T lymphocyte proliferation through activation of P53 and inhibition of ERK1/2 signaling pathway in children with Kawasaki disease. Eur Rev Med Pharmacol Sci. 2017;21(16):3714–3722.
   PubMed Web of Science ®Google Scholar
• Wang X, Ding YY, Chen Y, et al. MiR-223-3p alleviates vascular endothelial injury by targeting IL6ST in kawasaki disease. Front Pediatr. 2019;7:288.
   PubMed Web of Science ®Google Scholar